Emily Riser

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Rationale and design of the tele-exercise and multiple sclerosis (TEAMS) study: A comparative effectiveness trial between a clinic- and home-based telerehabilitation intervention for adults with multiple sclerosis (MS) living in the deep south

James H. Rimmer, Mohanraj Thirumalai, Hui‐Ju Young et al. · Contemporary Clinical Trials · 2018 · 46 citations

Rehabilitation Process, Physical Activity, Kinesiology +15

COVID-19 Modifications for Remote Teleassessment and Teletraining of a Complementary Alternative Medicine Intervention for People With Multiple Sclerosis: Protocol for a Randomized Controlled Trial

Byron Lai, Chia-Ying Chiu, Emily Pounds et al. · JMIR Research Protocols · 2020 · 39 citations · Full text

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis

Guy J. Buckle, Daniel S. Bandari, Jeffrey I. Greenstein et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2020 · 12 citations · Full text